Bone Graft Substitutes Market Insights, Trends, and Outlook during Forecast period 2022-2028

 

Bone Graft Substitutes Market

Bone Grafting is a surgical process in which deficient bone is replaced. In bone grafting treatments, many types of bone grafts are employed, including autologous bone grafts, allografts, and synthetic bone grafts. Over the projected period, the market is likely to rise due to rising usage of bone graft alternatives such as ceramics, polymers, bioactive glass, and others. Over the forecast period, technological advancements in the incorporation of human growth factors into bone grafts with osteoconductive and osteoinductive properties, such as demineralized bone matrix, bone morphogenetic proteins, and platelet rich plasma (PRP), are expected to provide market players with growth opportunities to establish a strong position in the global bone graft and substitutes market.

Researchers are working to produce novel bone transplants for the treatment of bone diseases. For example, in 2015, Texas A&M University scientists developed a novel synthetic material- a biodegradable scaffold- to bridge the gaps for new bone formation in order to enhance grafting therapies for patients with bone abnormalities and tumours. The rising frequency of bone cancer is likely to drive demand for bone grafts and replacements, propelling the worldwide Bone Graft Substitutes Market forward throughout the forecast period. According to the American Society of Clinical Oncology (ASCO), roughly 3,450 persons of all ages were diagnosed with primary bone cancer in the United States in 2017. As a result, new occurrences of bone cancer are predicted to fuel the disease's progression.

One grafts are implanted materials with osteoconductive, osteogenic, and osteoinductive qualities that stimulate bone healing, bone production, and osseous repair. Sports, trauma, plastic, facial, and spinal operations all employ them. They can also be utilised to fill cavities in the absence of bones or to assist provide structural stability. Bone grafting is a medical treatment that involves using a substance (bone graft) from a patient's own body, a corpse, animals, or a different person to replace a missing or defective bone. It's used for wound healing, difficult fracture repair, and other things.

The rise in incidence of musculoskeletal disorders, the development of biocompatible synthetic bone grafts, technological advancements in the medical field leading to a shift from autograft to allograft, and an increase in demand for dental bone grafts are all driving the global bone grafts and substitutes market. However, the market for bone grafts and replacements is expected to be constrained by rising surgical costs and ethical concerns surrounding bone grafting operations. Conversely, leading companies' increased focus on R&D efforts in bone grafts and replacements, as well as an increase in demand for orthopaedic operations among the senior population, are projected to present profitable prospects for market participants in the future.

The overall impact of the COVID-19 pandemic on medical device businesses in the bone grafts & replacements sector is anticipated to be unfavourable. Companies are experiencing a setback as a result of the shutdown, which has caused supply chain problems all across the world. Furthermore, significant industry participants are having difficulty finding human resources to manufacture bone grafts and replacements at manufacturing sites. In addition, end users like as hospitals and clinics have reported a decrease in patient visits as a result of the global lockdown limitations. However, the situation is anticipated to improve as governments across the world begin to reduce regulations to allow businesses to resume operations. Moreover, the demand for bone grafts & substitutes is likely to increase post recommencing the elective surgeries and procedures in the near future.

Key players operating in the global bone graft and substitutes market include Ace Surgical Supply Co., Inc., NovaBone Product, LLC., Exactech, Inc., Medtronic Plc., LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation., BioHorizons Implant Systems, Inc., Globus Medical, Inc., RTI Surgical, Inc., Geistlich Pharma, Megagen, Novadip Biosciences, Mesoblast Ltd., Alphatec Spine, Inc., Institut Straumann AG, NuVasive, Inc., OsteoMed LLC, KYERON Medical Innovations, ORTHOFIX INTERNATIONAL N.V., Johnson & Johnson, Bone Therapeutics SA, K2M Group Holdings, Inc., and OsteoNovus